Lymphoma Partnering 2007-2013
The report provides an analysis of lymphoma partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors lymphoma technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.
This data driven report contains over 100 links to online copies of actual lymphoma deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.
The initial chapters of this report provide an orientation of lymphoma partnering trends.
Chapter 1 provides an introduction to the report, whilst
Chapter 3 provides an overview of the leading lymphoma deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of lymphoma partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of lymphoma technologies and products.
Lymphoma Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to lymphoma trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
- Trends in lymphoma dealmaking in the biopharma industry since 2007
- Access to summary headline, upfront, milestone and royalty data
- Access to over 100 lymphoma contract documents
- The leading lymphoma deals by value since 2007
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type
Chapter 1 Introduction
Chapter 2 Trends in lymphoma partnering
2.2. Lymphoma partnering over the years
2.3. Bigpharma lymphoma dealmaking activity
2.4. Lymphoma partnering by deal type
2.5. Lymphoma partnering industry sector
2.6. Lymphoma partnering by stage of development
2.7. Lymphoma partnering by technology type
2.8. Disclosed financial deal terms for lymphoma partnering
2.8.1 Lymphoma headline values
2.8.2 Lymphoma upfront payments
2.8.3 Lymphoma milestone payments
2.8.4 Lymphoma royalty rates
3.2. Top lymphoma deals by value
3.3. Top lymphoma deals involving bigpharma
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type
Diagnostic - companion
In vitro models
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendix 1 Deal type definitions
About Wildwood Ventures
Recent titles from CurrentPartnering
Order Form Reports
List of Chart
Figure 1: Lymphoma partnering since 2007
Figure 2: Bigpharma top 50 lymphoma deals 2007 to 2011
Figure 3: Bigpharma lymphoma deal frequency 2007 to 2011
Figure 4: Lymphoma partnering by deal type since 2007
Figure 5: Lymphoma partnering by industry sector since 2007
Figure 6: Lymphoma partnering by stage of development since 2007
Figure 7: Lymphoma partnering by technology type since 2007
Figure 8: Lymphoma deals with a headline value
Figure 9: Lymphoma deals with upfront payment values
Figure 10: Lymphoma deals with milestone payments
Figure 11: Lymphoma deals with royalty rates, %
Figure 12: Top lymphoma deals by value since 2007
Figure 13: Top lymphoma deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions
Ask for discount before buying this report
Please fill the enquiry form below.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org